![](https://monteverdelaw.com/wp-content/uploads/case-logo/urovant-sciences-ltd.png)
Urovant Sciences Ltd. (UROV) relating to its proposed acquisition by Sumitovant Biopharma Ltd. Under the terms of the agreement, Urovant shareholders are expected to receive approximately $16.25 in cash per share.
Urovant Sciences Ltd. (UROV) relating to its proposed acquisition by Sumitovant Biopharma Ltd. Under the terms of the agreement, Urovant shareholders are expected to receive approximately $16.25 in cash per share.